中药多糖治疗肺纤维化的多药理活性:概念与未来展望
肺纤维化是致命的慢性进行性呼吸系统疾病,现有药物存在局限。本文综述了中药多糖的来源、药物活性及对肺纤维化靶点的保护作用,旨在为多糖类药物的设计开发与潜在临床治疗药物提供参考。
要点
- 中药多糖在肺纤维化治疗中受到广泛关注。
- 综述汇总了多糖来源、药物活性及靶点保护作用。
- 为多糖类潜在临床治疗药物的开发提供参考。
核心结论
- 中药多糖在肺纤维化治疗中具有多药理活性,值得进一步开发为潜在临床治疗药物。
研究设计与样本
- 综述类文章,检索范围未在摘要中报告。
主要发现
- 综述总结了中药多糖的来源、药物活性及对肺纤维化靶点的保护作用。
临床怎么用
- 为研究人员设计和开发多糖类药物提供参考,指向潜在临床治疗用途。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary fibrosis is a fatal chronic progressive respiratory disease, characterized by continuous scarring of the lung parenchyma, leading to respiratory failure and death. The incidence of PF has increased over time. There are drugs, yet, there are some limitations. Hence, it is of importance to find new therapies and new drugs to replace the treatment of pulmonary fibrosis. In recent years, there have been a great number of research reports on the treatment of traditional Chinese medicine polysaccharides in various system fields. Among them, the treatment of PF has also gained extensive attention. This review summarized the source of polysaccharides, the drug activity of traditional Chinese medicine, and the protective effects on targets of Pulmonary fibrosis. We hope it can inspire researchers to design and develop polysaccharides, serving as a reference for potential clinical therapeutic drugs.
引用
- Wu X, Huang J, Wang J, et al. Multi-Pharmaceutical Activities of Chinese Herbal Polysaccharides in the Treatment of Pulmonary Fibrosis: Concept and Future Prospects. Front Pharmacol. 2021. PMID: 34489700. doi:10.3389/fphar.2021.707491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。